Egypt's Health Minister reviews upgrades at Gustave Roussy Hospital
During the meeting, Abdel Ghaffar stressed the importance of providing a supportive and comfortable environment for patients and their families. He directed the establishment of a dedicated unit to receive patient complaints and measure satisfaction, alongside streamlining medical and administrative procedures to enhance service delivery. The minister also called for strengthened coordination to ensure the continuous availability of essential medications and medical supplies.
Abdel Ghaffar highlighted that over 12,000 state-funded treatment approvals were issued between 1 June and 18 July 2025. He further emphasised the need to accelerate the work of health insurance medical committees to speed up insurance approvals for patients.
Ministry spokesperson Hossam Abdel Ghaffar announced the formation of a special task force to oversee the hospital's development plans and improvements to the work environment. This task force will implement regular reporting mechanisms to track performance and ensure sustained progress.
The minister also instructed an increase in the number of highly trained medical and administrative staff and called for expanded cooperation with French experts from Gustave Roussy to train Egyptian teams in advanced treatment protocols.
The Health Ministry reaffirmed its commitment to rigorous oversight of the hospital's operations, in coordination with the private sector, to guarantee equitable access to quality healthcare. It also highlighted its strategic partnership with Gustave Roussy International, aimed at improving patient outcomes and elevating standards of care.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Egypt Independent
4 hours ago
- Egypt Independent
'100 Days of Health' provides over 5mn free medical services in 3 days
Ministry of Health and Population announced on Saturday 19/7/2025 that a total of 5,063,722 free medical services were provided throughout three days since the launch of the third edition of the '100 Days of Health' campaign, which was launched on July 15, 2025. The campaign, which is implemented in accordance with the directives of Khaled Abdel Ghaffar, the Deputy Prime Minister for Human Development and Minister of Health and Population, aims to improve healthcare services across the state. As many as 1,570,726 services were provided by the campaign on Friday, according to Health Ministry Spokesman Hossam Abdel Ghaffar. He added that the campaign had provided 616,883 services through the primary healthcare and family planning sector, 362,407 services via the therapeutic care sector, 205,377 services from health insurance organization hospitals and 5,402 emergency services delivered by the Egyptian Ambulance Organization. Moreover, the campaign had offered health awareness and educational services to 85,681 persons through community outreach teams deployed in public spaces, clubs, and shopping malls across governorates, the spokesman added.
Daily News Egypt
13 hours ago
- Daily News Egypt
Sandoz Egypt introduces OMNITROPE 15mg biosimilar growth hormone for the treatment of short stature
Sandoz the global leader in generic and biosimilar medicines, announced the introduction of its 15mg/1.5ml concentration of the OMNITROPE biosimilar growth hormone for the treatment of short stature to the Egyptian market, as part of its ongoing efforts to support Egypt's Vision 2030. Local healthcare authorities remain committed to addressing various health challenges to enhance public health for current and future generations, and help build a healthier, more productive workforce. Research conducted at the Suez Canal University endocrinology outpatient clinic in Ismailia City, Egypt and released in 2024, underscored the importance of short stature treatment, with findings indicating that treatment with growth hormone significantly improved physical, social, psychological, and environmental quality of life¹. 'In children and adolescents, growth hormone is used to treat growth disturbance due to insufficient secretion of growth hormone, associated with Turner syndrome, with chronic renal insufficiency, in short children/adolescents born small for gestational age, or associated with Prader-Willi syndrome (PWS). The biosynthetic/synthetic hormone is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (GH)² ³,' Dr. Mona Salem, Professor of Paediatric Endocrinology at Ain Shams University and President of the Egyptian Society of Paediatric Endocrinology & Diabetes, said. 'Short stature is diagnosed in children or adolescents who are well below the average height for their age and gender, which may be due to genetic factors or underlying health conditions⁴ ⁵. Studies show that short stature prevalence varies geographically, with a genetic predisposition, as well as nutritional and environmental factors, playing an important role⁶,' Dr Salem added. A cross-sectional study conducted between January 2018 and January 2020 involving 33,150 Egyptian children aged 6 to 11 showed that 17% of the sample had short stature, with 40.8% attributed to familial factors and 24.2% to constitutional causes⁷. 'As noted, short stature affects children and adolescents, not only physically but also psychologically' Dr. Rasha Tarif, Head of the Paediatric Endocrinology Unit at Ain Shams University and Chair of European Society for Paediatric Endocrinology (ESPE) Education and Training Committee, said. 'Growth hormone plays a critical role in effective treatment plans, but ensuring its availability has been a challenge in recent years. This challenge is being addressed through ongoing efforts to secure sufficient quantities to ensure uninterrupted treatment until puberty is complete. Treatment continuity, along with proper follow-up with a specialized physician, is essential for achieving optimal results,' Dr. Tarif added. This new concentration is being made available, expanding treatment options in line with the latest global scientific standards. This will allow for a better patient response in the treatment journey by minimizing interruptions. Securing the reliable availability of this human growth hormone reinforces medical efforts to provide comprehensive care for children and reflects the Egyptian medical community's commitment to delivering advanced treatment solutions for patients in need. 'The Egyptian government, within the context of the Egypt Vision 2030, has shown strong commitment to reducing the prevalence of short stature among children, aiming to improve public health for current and future generations, and help build a healthier, more productive workforce, in line with the national vision for sustainable development,' Sameh Elbagoury, Sandoz Egypt Country Head, said. 'Our top priority at Sandoz is to develop affordable biosimilars for high-quality biologics and ensure that as many patients as possible have access to them. Introducing the 15 mg concentration of our well-established Omnitrope growth hormone allows us to help local authorities meet the increase in demand for growth hormones, reflecting the positive impact and notable success achieved by the Presidential Initiative for the Early Detection of Anaemia, Obesity and Short Stature,' Elbagoury added.
Daily News Egypt
19 hours ago
- Daily News Egypt
Egypt's Health Minister reviews upgrades at Gustave Roussy Hospital
Egypt's Minister of Health and Population, Khaled Abdel Ghaffar, convened a meeting at the ministry's headquarters in the New Administrative Capital to review the quality of medical services provided at Gustave Roussy Hospital (formerly Al-Hermel). The meeting underscored the government's commitment to delivering high-quality healthcare to citizens, according to an official statement released on Saturday. During the meeting, Abdel Ghaffar stressed the importance of providing a supportive and comfortable environment for patients and their families. He directed the establishment of a dedicated unit to receive patient complaints and measure satisfaction, alongside streamlining medical and administrative procedures to enhance service delivery. The minister also called for strengthened coordination to ensure the continuous availability of essential medications and medical supplies. Abdel Ghaffar highlighted that over 12,000 state-funded treatment approvals were issued between 1 June and 18 July 2025. He further emphasised the need to accelerate the work of health insurance medical committees to speed up insurance approvals for patients. Ministry spokesperson Hossam Abdel Ghaffar announced the formation of a special task force to oversee the hospital's development plans and improvements to the work environment. This task force will implement regular reporting mechanisms to track performance and ensure sustained progress. The minister also instructed an increase in the number of highly trained medical and administrative staff and called for expanded cooperation with French experts from Gustave Roussy to train Egyptian teams in advanced treatment protocols. The Health Ministry reaffirmed its commitment to rigorous oversight of the hospital's operations, in coordination with the private sector, to guarantee equitable access to quality healthcare. It also highlighted its strategic partnership with Gustave Roussy International, aimed at improving patient outcomes and elevating standards of care.
